News Related to Reversible Covalent BTK Inhibitor

Related coverage linked through entity extraction aliases.

Sanofi's Rilzabrutinib Gains Regulatory Designations in Japan and U.S. for Rare Diseases

Mar 03, 2026

Sanofi's oral BTK inhibitor rilzabrutinib received orphan drug designation in Japan for IgG4-related disease and warm autoimmune hemolytic anemia, while also securing U.S. FDA breakthrough therapy designation for the rare anemia indication.

Sanofi's Rilzabrutinib Receives Orphan Drug Designation in Japan for IgG4-Related Disease

Mar 02, 2026

Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to Sanofi's rilzabrutinib for IgG4-related disease, marking the third global orphan designation for this indication based on positive phase 2 study data.